Tirzepatide improves how physically capable people feel

Weight-loss drugs are usually judged on kilograms lost and blood markers improved, but what people notice day to day is whether they can move, climb stairs and get through life more easily. Patient-reported physical function is the measure closest to that lived experience. Tirzepatide is known to produce substantial weight loss in trials, yet whether that translates into people actually feeling more physically capable is a separate question worth answering in its own right. This review set out to pool the randomised evidence on validated physical-function outcomes.

The authors searched PubMed, Embase and the Cochrane Library up to 20 July 2025 for randomised controlled trials comparing once-weekly tirzepatide at 10 or 15 mg with placebo, provided they reported validated physical function outcomes. Six trials comprising 4531 participants were included, of whom 2802 received tirzepatide. The primary endpoints were changes from baseline in the SF-36 physical function domain and the IWQOL-Lite-CT physical function subscale. Random-effects models produced pooled mean differences, heterogeneity was assessed with I2 statistics, and the certainty of evidence was rated with GRADE.

Tirzepatide significantly improved physical function versus placebo on both measures: a mean difference of 2.26 points on the SF-36 physical function domain (95% CI 1.76 to 2.76) and 10.10 points on the IWQOL-Lite-CT physical function subscale (95% CI 8.61 to 11.60). Subgroup analyses showed consistent benefits at both the 10 mg and 15 mg doses. However, between-study heterogeneity was extreme, at I2 = 99.8% for both endpoints. The overall certainty of evidence was rated moderate under GRADE, held down by risk of bias and inconsistency across the included studies.

Tirzepatide's effects on weight are well documented; this analysis adds a quality-of-life dimension, suggesting the drug also shifts how physically capable people report feeling. That extends the case for these drugs beyond scale weight. But the picture is complicated by the near-total heterogeneity between trials, which the authors themselves say limits the interpretability of the pooled numbers. It also leaves open whether self-reported gains would show up on objective performance tests, since these endpoints were questionnaires rather than measured physical tasks.

This is a reason to think the benefits of major weight loss on these drugs may extend beyond the number on the scales to how people experience their own bodies: perceived mobility and physical capability improved in pooled trials. It is not proof of better measured performance, because the outcomes were self-reported, and the extreme variation between studies means the size of the effect is genuinely uncertain. For anyone weighing up what these medicines do, the takeaway is directional rather than precise.